Some body tissues are basically leafy suburbs. Others feel more like a chaotic block where the streetlights flicker, the rules get bent, and the local troublemakers know exactly how to dodge security. Advanced squamous lung cancer lives in one of those rough neighborhoods - and this new phase 3 trial asks whether a smarter security combo can finally stop the usual suspects from running the place.
The paper, published in The Lancet, compared ivonescimab plus chemotherapy with tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer, or NSCLC.[1] And yes, that is a mouthful. Cancer immunotherapy has an annoying habit of sounding like someone spilled Scrabble tiles into a spreadsheet.
The quick version: one drug, two jobs
Here’s the trick that makes ivonescimab interesting. It is a bispecific antibody, meaning it goes after two targets at once: PD-1 and VEGF.
If you hang around immunology long enough - which I recommend, we have excellent molecular drama - you learn that tumors survive partly by pulling off two heists at once:
- They slam the brakes on T cells through immune checkpoint pathways like PD-1
- They build messy, abnormal blood vessels using VEGF, which helps feed the tumor and creates a sketchy microenvironment where immune cells struggle to operate
So ivonescimab is trying to unmask the villain and cut off the getaway route. It is part immune reboot, part vascular sabotage. Very spy thriller. Very "remove the fake mustache and disable the escape car."
By contrast, tislelizumab is a PD-1 inhibitor, so it tackles the immune checkpoint side but not VEGF directly.
What this trial actually found
The HARMONi-6 trial enrolled 532 patients in China with previously untreated, advanced squamous NSCLC. Patients got either:
- Ivonescimab + paclitaxel + carboplatin, then maintenance ivonescimab
or - Tislelizumab + paclitaxel + carboplatin, then maintenance tislelizumab[1]
This was a randomized, double-blind, phase 3 trial, which is the grown-up table of cancer research. Not perfect, because nothing involving human biology ever is, but definitely not vibes-based medicine.
At the interim overall survival analysis, the results favored ivonescimab:
- Median overall survival: 27.9 months vs 23.7 months
- Hazard ratio for death: 0.66
That means the risk of death during the study period was about 34% lower in the ivonescimab group than in the tislelizumab group.[1]
That is not a tiny statistical blip hiding in the weeds. For advanced squamous lung cancer, where progress has often been measured in frustratingly modest increments, a survival gain like this gets attention fast.
Why people are paying attention
Squamous NSCLC has been a harder nut to crack than many of us would like. Some targeted therapies that transformed treatment in other lung cancer subtypes never really showed up to the party here. So for many patients, the backbone of treatment still involves chemo plus immunotherapy.[2]
What makes this study interesting is that it tests a theory researchers have been circling for a while: maybe blocking immune suppression and tumor blood-vessel signaling together works better than checkpoint blockade alone.
And biologically, that idea makes sense. VEGF does more than help tumors grow blood vessels. It also seems to help build an immune-hostile environment - almost like the tumor hires bad urban planners and corrupt bouncers at the same time. Reviews over the last few years have argued that combining anti-angiogenic therapy with immune checkpoint inhibitors could improve T-cell infiltration and function in NSCLC and other cancers.[2,3]
Which, if you are a T-cell fan like me, is catnip. T cells are the underpaid action heroes of this whole story. Give them access, remove the fake ID checks, and suddenly the mission looks a lot less impossible.
The catch, because there is always a catch
Before we all run through the streets throwing confetti made of Kaplan-Meier curves, a few caveats.
First, this is an interim overall survival analysis, not the final word.[1] The signal is strong, but we still want longer follow-up.
Second, the trial was conducted in China, so the next big question is how well these results translate across broader global populations and health systems.
Third, whenever you combine immune therapy, chemo, and VEGF-related strategies, side effects matter a lot. VEGF blockade can bring its own baggage, including bleeding, hypertension, and proteinuria in some settings.[3,4] The basic challenge is always the same: can you hit the tumor harder without making life miserable for the patient?
That is the entire oncology tightrope, basically.
What this could mean in the real world
If these findings hold up and are reproduced, ivonescimab could become a serious new first-line option for patients with advanced squamous NSCLC. That matters because first-line therapy is your best shot to change the arc of disease early, before the tumor gets more chances to adapt, spread, and generally behave like a tiny criminal enterprise with excellent crisis management.
It also nudges the field toward a broader idea: next-generation immunotherapy may not be about just taking one brake off the immune system. It may be about coordinating multiple pressure points at once - immune checkpoints, blood vessels, stromal barriers, and the whole suspicious neighborhood around the tumor.
That is where things get exciting. Also complicated. Also expensive. Also likely to involve acronyms that look fake. But exciting.
References
-
Lu S, Liu B, Luo Y, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet. 2026. doi:10.1016/S0140-6736(26)00966-9
-
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol. 2023;41(6):1200-1212. doi:10.1200/JCO.22.01427
-
Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17-35. doi:10.1016/j.immuni.2019.12.011
-
Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas: an open-label, phase 1a/b study. Lancet Oncol. 2021;22(9):1284-1295. doi:10.1016/S1470-2045(21)00337-8
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.